Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial

Journal:

Nature Medicine

Published:

2026-01-15

DOI:

10.1038/s41591-025-04071-1

Affiliations:

9

Authors:

12

Go to article

Institutions	Authors	Share
Lilly, United States of America (USA)	5.000000	0.42
Brigham and Women's Hospital (BWH), United States of America (USA)	2.000000	0.17
University of California, San Diego (UC San Diego), United States of America (USA)	1.000000	0.08
Mayo Clinic, United States of America (USA)	1.000000	0.08
Weill Cornell Medicine, United States of America (USA)	1.000000	0.08
Yale University, United States of America (USA)	1.000000	0.08
Woolcock Institute of Medical Research (WIMR), Australia	0.333333	0.03
Macquarie University, Australia	0.333333	0.03
Royal Prince Alfred Hospital (RPAH), USYD, Australia	0.333333	0.03

Interested in Cardiovascular Medicine and Haematology?